Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03677076 · ClinicalTrials.gov registry record
Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 14
- Enrollment target
NCT03677076 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 14 participants.
The verdict
NCT03677076 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This study is for patients with metastatic prostate cancer receiving radium-223 as their standard of care therapy. The researchers will collect blood and urine samples from patients before, during and after the radium-223 therapy. The researchers will compare these samples to observe how the treatment has affected different cancer markers.
Interventions
- OTHER Ancillary/Correlative
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03677076
The ClinicalTrials.gov registry entry for NCT03677076 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ancillary/Correlative is the first listed.
NCT03677076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03677076 about?
NCT03677076 is a clinical study titled "Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer". This study is for patients with metastatic prostate cancer receiving radium-223 as their standard of care therapy. The researchers will collect blood and urine samples from patients before, during and after the radium-223 therapy. The researchers will compare these samples to observe how the treatme...
What is the current status of trial NCT03677076?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2019-03-04. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03677076?
The interventions under investigation include: Ancillary/Correlative (OTHER).
Who is sponsoring clinical trial NCT03677076?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.